Actavis bets $675M-plus on Durata and its antibiotic Dalvance

Actavis ($ACT) snapped up Durata Therapeutics ($DRTX) and its IV antibiotic for skin infections, Dalvance, in a bid to expand its infectious disease portfolio. U.S.-based Actavis will shell out $675 million in cash up front, or $23 per share, plus up to $5 per share in sales milestone payments. Release

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.